https://www.selleckchem.com/products/pfi-6.html
[ Tc]Tc-maSSS-PEG -RM26 had tumor-to-blood, tumor-to-muscle, and tumor-to-bone ratios of 97 ± 56, 188 ± 32, and 177 ± 79, respectively. SPECT/CT images of [ Tc]Tc-maSSS-PEG -RM26 clearly visualized the GRPR-overexpressing tumors. The dosimetry estimated for [ Tc]Tc-maSSS-PEG -RM26 showed the highest absorbed dose in the small intestine (1.65 × 10 mGy/MBq), and the effective dose is 3.49 × 10 mSv/MBq. The GRPR antagonist maSSS-PEG -RM26 is a promising GRPR-targeting agent that can be radiolabeled through a single-step with the generator-pr